Accord Logo

Intended for UK patients and members of the public

Victanyl Patches

Active Ingredients

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Victanyl 100 micrograms/hour Transdermal Patch Fentanyl

PL Number:
0142/1161
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Active

Product Documentation

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    PIL sections updated: Introduction, 2, 3, 4 and 6.

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    SmPC Sections updated: 4.4, 4.8 and 10.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Victanyl 12 micrograms/hour Transdermal Patch

PL Number:
0142/1040
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Active

Product Documentation

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 12 micrograms/hour transdermal patch (PL 00242/0409; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additionally, section 2 of the SmPC has been updated with an additional warning pertaining to the product name and editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    PIL sections updated: Introduction, 2, 3, 4 and 6.

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 12 micrograms/hour transdermal patch (PL 00242/0409; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additionally, section 2 of the SmPC has been updated with an additional warning pertaining to the product name and editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    SmPC Sections updated: 2, 4.4, 4.8 and 10.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Victanyl 25 micrograms/hour Transdermal Patch Fentanyl

PL Number:
0142/1158
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Active

Product Documentation

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    PIL sections updated: Introduction, 2, 3, 4 and 6.

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    SmPC Sections updated: 4.4, 4.8 and 10.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Victanyl 50 micrograms/hour Transdermal Patch fentanyl

PL Number:
0142/1159
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Active

Product Documentation

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    PIL sections updated: Introduction, 2, 3, 4 and 6.

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    SmPC Sections updated: 4.4, 4.8 and 10.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Victanyl 75 micrograms/hour Transdermal Patch fentanyl

PL Number:
0142/1160
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Active

Product Documentation

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    PIL sections updated: Introduction, 2, 3, 4 and 6.

  • Description of update: To update section 4.4 of the SmPC in line with the reference product, Durogesic DTrans 25 micrograms/hour transdermal patch (PL 00242/0192; MAH: Janssen-Cliag Limited) dated 23rd August 2023. Consequently, the leaflet has been updated. Additional editorial updates have been made to the PIL. To update section 4.8 of the SmPC in line with the PRAC recommendation PSUSA/00001370/202304 (dysphagia). Consequently, the leaflet has been updated.

    SmPC Sections updated: 4.4, 4.8 and 10.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

General FAQs

For any further assistance, please get in touch.

View product information as a: